Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 5, 2011, Pages 506-511

  De Luis, D A ^a   Sagrado, M González ^a   Aller, R ^a   Izaola, O ^a   Conde, R ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Cannabinoid receptor gene; Metabolic syndrome; Obesity; Polymorphism

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR; GLUCOSE; INSULIN;

ADULT; ARTICLE; BLOOD PRESSURE; CANNABINOID 1 RECEPTOR GENE; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IMPEDANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MUTANT; OBESITY; PRIORITY JOURNAL; RECEPTOR GENE; WILD TYPE;

CROSS-SECTIONAL STUDIES; HUMANS; METABOLIC SYNDROME X; OBESITY; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1;

EID: 79960187115     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1200     Document Type: Article

References (29)

1. Ameri A. The effects of cannabinnoids on the brain. Prog Neurobiol 1999; 58: 315-348.
2. Brown SM, Warger-Miller J, Mackie K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 2002; 1576: 255-264.
3. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998; 38: 179-200.
4. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13: 321-323.
5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(5): 683-689.
6. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-1607.
7. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83(9B): 25F-29F.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
9. Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis: an improved method for nutritional follow up. Clin Res 1993; 41: 53-54.
10. Mataix J, Mañas M. Tablas de Composición de Alimentos Españoles. University of Granada: Granada, Spain, 2003.
11. Duart MJ, Arroyo CO, Moreno JL. Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 2002; 40: 1161-1167.
12. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
13. Pfutzner A, Langefeld M, Kunt T, Lobig M. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-576.
14. Meier U, Gressner M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.
15. Suominen P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 2004; 50: 219-221.
16. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO Europe Study group. Effects of the cannabinoid 1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: one year experience from the RIO Europe study. Lancet 2005; 365: 1389-1397.
17. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
18. Engeli S, Jana B, Mareike F, Kerstin G, Jürgen J, Sandor B. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
19. Gazzerro P, Caruso MG, Notarnicola M, et al. Association between cannabinoid type 1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes 2007; 31: 908-912.
20. Jaeger J, Mattevi V, Callegari-Jacques SD, Hutz MH. Cannabinoid type 1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Disease Markers 2008; 25: 67-74.
21. Russo P, Strazzullo P, Cappuccio F, et al. Genetic variations at the endocannabinoid type 1 receptor gene (CRN1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007; 92: 2382-2389.
22. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the endocannabinoid receptor gene is associated with abdominal adiposity in obese men. Endocrinology 2007; 31: 138-141.
23. Benzinou M, Chevre JC, Ward K, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index European population. Hum Mol Genet 2008; 17: 1916-1921.
24. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics 2008; 9: 1647-1656.
25. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
26. Aberle J, Flitsch J, Alessia N, et al. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab 2008; 95: 188-191.
27. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A. The CB1 receptor antagonist rimonabant reverses the diet induced obesity phenotype through the regulation of lipolisis and energy balance. FASEB J 2005; 19: 1567-1569.
28. Bensaid M, Gary Bobo M, Esclangron A, Maffrand JP, Le Fut G, Oury Donat F. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp 30 mRNA expression in adipose tissue of obese fa/fa rats and in culture adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
29. Poirier B, Bidoauard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65-72.